NBTXStockNanobiotix - ADR
Verdicts genuinely change. Free email alert the moment NBTX's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Nanobiotix - ADR (NBTX) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-06-01). See the full ratio breakdown and business-activity screen below for the reasoning. ⚠️ This provider verdict is about 3 months old (2026-06-01) — older than one reporting quarter, so it may predate the financial data shown below.
This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $2.0B as of 2026-09-06. At the 2026-11-18 close it is about $1.4B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 0.0% (0.0% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 4.3% (3.1% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Unverified⚠️ debt implausibly low vs. real finance costs 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 30.00% | Pass(30.0pp buffer) |
| Interest-bearing investments | 3.09% | 30.00% | Pass(26.9pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Usmani Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Interest-bearing investments | 77.85% | 33.00% | Fail(44.8pp over) |
| Non-liquid assets | 22.15% | at least 20.00% | Pass(2.2pp above the floor) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 77.85% | 33.33% | Fail(44.5pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
FTSE Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 77.85% | 33.33% | Fail(44.5pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Dow Jones Islamic Market Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Cash + interest-bearing securities | 4.27% | 33.00% | Pass(28.7pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
S&P Shariah Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Cash + interest-bearing securities | 5.61% | 49.00% | Pass(43.4pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI M-Series Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed 3 of 3 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 5.61% | 33.33% | Pass(27.7pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from NBTX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $36.8M | 2025-12-31 | Revenue |
| Interest-bearing debtShort and long-term borrowings | $0 | 2025-12-31 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $62.0M | 2025-12-31 | CashAndCashEquivalents |
| Total assetsBalance sheet total | $79.6M | 2025-12-31 | Assets |
| Market capDenominator for AAOIFI | $2.0B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $634.7M | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $813.9M | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2025-12-31 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2025-12-31. Income statement as of 2025-12-31. Screened 2026-09-06.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$79.6M
Assets· balance sheet as of 2025-12-31 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2025-12-31 -
Cash and interest-bearing securities$62.0M
CashAndCashEquivalents· balance sheet as of 2025-12-31 -
Revenue$36.8M
Revenue· income statement as of 2025-12-31 -
Interest income (non-permissible)$0
no interest-income tag reported in 3+ years (treated as $0)· income statement as of 2025-12-31 -
Market cap$2.0BMarket-data quote at screen time, 2026-09-06 · not a filing figure, so no link
What changed, and when
Verdict history for NBTX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for NBTX has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | — |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| ALNYAlnylam Pharmaceuticals Inc | $31.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | $11M | 0.0% | 2026-09-30 |
| Israel Englander | Millennium Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.80 | NEUTRAL |
| Stochastic %K (14) | 5.81 | BUY |
| CCI (20) | -146.27 | BUY |
| Williams %R (14) | -94.19 | BUY |
| MACD (12,26,9) | -0.37 | SELL |
| ROC (10) | -9.43 | SELL |
| Momentum (10) | -2.80 | SELL |
| EMA (10) | 29.55 | SELL |
| SMA (10) | 30.43 | SELL |
| EMA (20) | 29.65 | SELL |
| SMA (20) | 30.72 | SELL |
| EMA (30) | 29.81 | SELL |
| SMA (30) | 28.06 | SELL |
| EMA (50) | 30.75 | SELL |
| SMA (50) | 29.72 | SELL |
| EMA (100) | 32.44 | SELL |
| SMA (100) | 34.73 | SELL |
| EMA (200) | 31.24 | SELL |
| SMA (200) | 34.41 | SELL |
About Nanobiotix - ADR
Healthcare · Biotechnology
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-10-28
Stop 34.07 Now 26.90 Target 35.10
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 12.0%, RSI in healthy zone. High conviction entry. Use `!plan NBTX [entry] [stop] [target]` to size the position properly.
Scores: 4 bullish / 0 bearish
No real edge — avoid
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 24 |
| 🕐 1H | BEARISH | 97 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.